Germany’s medicine regulator will allow certain patients with treatment-resistant depression to try psilocybin therapy, a major shift as psychedelics inch closer to mainstream medicine.
It is the first time in the European Union that psilocybin – the hallucinogenic compound in magic mushrooms – will be made available through a compassionate use scheme, in which patients with serious or life-threatening illnesses can get access to drugs that have not yet been approved.
